Rexobin Approved for Pustular Psoriasis Flares July 29, 2026 The NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treatment is intended for adults weighing at least 40 kilograms who experience flare-ups of generalized pustular psoriasis. The approval introduces an additional therapy for patients affected by this rare and severe inflammatory skin condition. The authorization was announced on July

Takeda China has received approval from the National Medical Products Administration (NMPA) for Orzeyful (oveporexton) as a treatment for Narcolepsy Type 1 (NT1). Also read: Germany Enacts 2026 Healthcare Reform to Curb Statutory Insurance Spending This authorization establishes Orzeyful as the first oral orexin receptor 2 (OX2R)-selective agonist in the Chinese market and represents the first therapy approved specifically to address the underlying physiological cause of the

HUTCHMED has secured conditional approval from China’s National Medical Products Administration for savolitinib, marketed as Orpathys, in a new gastric cancer indication. The decision allows oncologists to use Orpathys in adults with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma whose tumours harbor MET amplification and who have already been through at least two systemic treatment regimens. Also read: CVS Pharmacy Joins Medicare

China’s regulatory authority has approved Vanflyta (quizartinib) for adults with newly diagnosed acute myeloid leukemia (AML) harboring FLT3-ITD mutations, introducing a targeted therapy option into frontline treatment. The drug is to be used alongside standard induction and consolidation chemotherapy, followed by maintenance therapy. Also read: EULAR Annual Meeting in London, UK | 2026 The decision is supported by data from the phase 3 QuANTUM-First study, which showed that

China’s National Medical Products Administration (NMPA) has authorised Exdensur (depemokimab) as an add-on maintenance therapy for severe asthma with an eosinophilic phenotype in adults and adolescents aged 12 years and older. This decision makes Exdensur the first ultra-long-acting biologic available in China for this patient population, offering a new option for those whose disease remains uncontrolled despite standard treatment. Details of Phase III SWIFT-1 and SWIFT-2 tri

China’s National Medical Products Administration has authorised two innovative therapies licensed by Sanofi, strengthening treatment options in serious cardiovascular and lipid disorders. Myqorzo (aficamten) has been approved for adults with obstructive hypertrophic cardiomyopathy, while Redemplo (plozasiran) has been cleared to reduce triglyceride levels in adults with familial chylomicronaemia syndrome who require dietary management. iPharmaCenter Consulting: Find services

China’s National Medical Products Administration has officially cleared Nucala (mepolizumab) as a supplemental maintenance therapy for adults suffering from chronic obstructive pulmonary disease (COPD). This authorization specifically targets patients whose condition remains poorly managed and is linked to elevated levels of eosinophils in the blood. Nucala: A Milestone in Biological Respiratory Care Nucala stands as the inaugural monthly biological treatment in China indic

Enhertu (trastuzumab deruxtecan) has received marketing authorization in China as the first HER2‑targeting therapy for people with HER2‑low or HER2‑ultralow metastatic breast cancer whose disease has worsened after at least one endocrine treatment in the metastatic setting. The decision is supported by phase 3 DESTINY‑Breast06 data showing clinically meaningful improvements in progression‑free survival versus standard chemotherapy. New indication in China The National Medic

China’s NMPA has approved Pfizer’s matazisimab (You Ruiting) for routine prophylaxis in hemophilia A or B patients with inhibitors, backed by pivotal BASIS data

China’s National Medical Products Administration (NMPA) has approved Vyloytm (zolbetuximab) for use alongside fluoropyrimidine- and...

Nucala has become the first anti-interleukin-5 therapy approved in China for treating adults with chronic rhinosinusitis with nasal...

HUTCHMED and Innovent Biologics have announced that the China National Medical Products Administration (NMPA) has conditionally approved...

HUTCHMED has announced that the China National Healthcare Security Administration (NHSA) has renewed the inclusion of savolitinib in the...

The 2024 National Reimbursement Drug List (NRDL) unveiled by China's National Healthcare Security Administration adds 91 new drugs,...

AstraZeneca and Daiichi Sankyo’s drug, Enhertu (trastuzumab deruxtecan), have been granted conditional approval in China as a treatment...

China’s National Medical Products Administration (NMPA) has officially approved Padcev (enfortumab vedotin) for the treatment of adult...

Enhertu, developed by AstraZeneca and Daiichi Sankyo, has gained conditional approval in China for use in patients with advanced or...

HUTCHMED (China) Limited has announced that the New Drug Application (NDA) for tazemetostat, aimed at treating adult patients with...

Eisai and Biogen announced that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody, Leqembi (ecanemab) (known in...

China’s National Medical Products Administration (NMPA) has granted approval for AstraZeneca’s Tagrisso (osimertinib), combined with...

May 13, 2024 Eisai's Fycompa was approved for generalized tonic-clonic seizures Approved in China for the supplementary management of...

December 21, 2023 Takeda's Livtencity was approved in China for CMV infections Takeda declares the approval from China NMPA for...

Takeda announced that the National Medical Products Administration (NMPA) of China approved Exkivity (mobocertinib) for treating adults...

December 23, 2022 Eisai initiated data submission for BLA of lecanemab in China for Alzheimer's Eisai and Biogen announced that they have...